Dermatologic Adverse Events Associated With Use of Adjuvant Lapatinib in Combination With Paclitaxel and Trastuzumab for HER2-Positive Breast Cancer: A Case Series Analysis
Clinical Breast Cancer - United States
doi 10.1016/j.clbc.2015.11.001
Full Text
Open PDFAbstract
Available in full text
Date
June 1, 2016
Authors
Publisher
Elsevier BV